Management of cancer-associated thrombotic microangiopathy: What is the right approach?

American Journal of Hematology

Volumn 82, Issue 4, 2007, Pages 295-298

  Werner, Theresa L ^a,b   Agarwal, Neeraj ^a,b   Carney, Heather M ^b   Rodgers, George M ^a,b  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Management; Thrombotic microangiopathy

Indexed keywords

CORTICOSTEROID; PACLITAXEL; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANEMIA; BONE MARROW BIOPSY; BONE METASTASIS; BREAST CANCER; CASE REPORT; FEMALE; FEVER; HUMAN; NIGHT SWEAT; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RIB FRACTURE; SINGLE DRUG DOSE; THORAX PAIN; THROMBOTIC THROMBOCYTOPENIC PURPURA; WEIGHT REDUCTION;

ANEMIA, HEMOLYTIC; BONE NEOPLASMS; BREAST NEOPLASMS; CA-125 ANTIGEN; CARCINOMA, LOBULAR; FEMALE; HUMANS; MIDDLE AGED; PLASMA EXCHANGE; THROMBOCYTOPENIA; THROMBOSIS;

EID: 34147118102     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20783     Document Type: Review

References (24)

1. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000;109:496-507.
2. Ruggenenti P, Remuzzi G. Thrombotic thrombocytopenic purpura and related disorders. Hematol Oncol Clin North Am 1990;4:219-241.
3. Agarwal N, Cherascu B. Concomitant acral necrosis and haemolytic uraemic syndrome following ingestion of quinine. J Postgrad Med 200248:197-198.
4. Giroux L, Bettez P, Giroux L. Mitomycin-C nephrotoxicity: A clinico-pathologic study of 17 cases. Am J Kidney Dis 1985;6:28-39.
5. Nadir Y, Hoffman R, Brenner B. Drug-related thrombosis in hematologic malignancies. Rev Clin Exp Hematol 2004;8:E4.
6. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
7. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004;407-423.
8. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001;98:1765-1772.
9. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: The role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001;14:437-454.
10. George JN. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clin Adv Hematol Oncol 2005;3:627-632.
11. Fontana S, Gerritsen HE, Kremer Hovinga J, Furlan M, Lämmle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol 2001;113:100-102.
12. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004;103:4023-4049.
13. Studt JD, Kremer Hovinga JA, Albedo L, Bianchi V, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: Diagnostic experience 2001/ 2002 of a single research laboratory. Swiss Med Wkly 2003;133:325-332.
14. Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry. J Clin Oncol 1989;6:781-789.
15. Kressel BR, Ryan KP, Duong AT, et al. Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma. Cancer 1981;48:1738-1745.
16. Lohrmann HP, Adam W, Heymer B, et al. Microangiopathic hemolytic anemia in metastatic carcinoma: Report of eight cases. Ann Intern Med 1973;79:368-375.
17. von Bubnoff N, Sandherr M, Schneller F, Peschel C. Thrombotic thrombocytopenic purpura in metastatic carcinoma of the breast. Am J Clin Oncol 2000;23:74-77.
18. Brain MC, Azzopardi JG, Baker LR, Pineo GF, Roberts PD, Dacie JV. Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma. Br J Haematol 1970;18:183-192.
19. Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP. Microagniopathic hemolytic anemia and cancer: A review. Medicine 1979;58:377-384.
20. Moake JL, Chow TW. Thrombotic thrombocytopenic purpura: Understanding a disease no longer rare. Am J Med Sci 1998;316:105-119.
21. Kwaan HC, Soff GA. Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997;34:159-166.
22. Murgo A. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987;24:161-177.
23. von Bubnoff N, Sandherr M, Schneller F, Peschel C. Thrombotic thrombocytopenic purpura in metastatic carcinoma of the breast. Am J Clin Oncol 2000;23;74-77.
24. Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic uremic syndrome: Analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781-789.